1. Comprehensive proteomics profiling identifies patients with late gadolinium enhancement on cardiac magnetic resonance imaging in the hypertrophic cardiomyopathy population. (14th October 2021) Authors: Lander, B S; Zhao, Y; Hasegawa, K; Maurer, M S; Fifer, M A; Reilly, M P; Shimada, Y J Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Comprehensive proteomics profiling reveals molecular pathways that are differentially regulated in hypertrophic cardiomyopathy and correlate with clinical markers of disease severity. (14th October 2021) Authors: Shimada, Y J; Raita, Y; Liang, L W; Maurer, M S; Hasegawa, K; Fifer, M A; Reilly, M P Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. NNC6019–0001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): rationale and study design of a phase 2, randomized, placebo-controlled trial. (3rd October 2022) Authors: Fontana, M; Buchholtz, K; Engelmann, M D M; Grogan, M; Hovingh, G K; Kristen, A V; Poulsen, P; Shah, S J; Maurer, M S Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P3547Comparative effectiveness of alcohol septal ablation versus septal myectomy on acute cardiovascular events in patients with hypertrophic cardiomyopathy. (28th August 2018) Authors: Shimada, Y J; Goto, T; Takayama, H; Homma, S; Maurer, M S; Hasegawa, K Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P684Inotersen improved quality of life, polyneuropathy and cardiomyopathy in a diverse group of patients with hereditary transthyretin amyloidosis in the phase 3 study NEURO-TTR. (28th August 2018) Authors: Obici, L; Whelan, C J; Drachman, B M; Heitner, S B; Maurer, M S; Damy, T; Judge, D P; Monia, B P; Hughes, S G; Kwoh, J; Jung, B; Ackermann, E J; Benson, M D Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P685Hereditary transthyretin amyloidosis is associated with significant disease burden: analysis of the baseline characteristics of patients from the phase 3 study NEURO-TTR. (28th August 2018) Authors: Damy, T; Maurer, M S; Heitner, S B; Drachman, B M; Whela, C J; Judge, D P; Guthrie, S; Tai, L J; Hughes, S; Monia, B P; Ackermann, E; Benson, M D Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Prediction of major adverse cardiovascular events in patients with hypertrophic cardiomyopathy using proteomics profiling. (14th October 2021) Authors: Shimada, Y J; Raita, Y; Maurer, M S; Hasegawa, K; Fifer, M A; Reilly, M P Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using proteomics profiling. (3rd October 2022) Authors: Harano, N; Liang, L W; Hasegawa, K; Maurer, M S; Tower-Rader, A; Fifer, M A; Reilly, M P; Shimada, Y J Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Proteomics profiling reveals distinct molecular subtypes of hypertrophic cardiomyopathy with differential risks of major adverse cardiovascular events. (14th October 2021) Authors: Liang, L W; Raita, Y; Hasegawa, K; Fifer, M A; Maurer, M S; Reilly, M P; Shimada, Y J Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Proteomics profiling reveals signaling pathways associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy. (3rd October 2022) Authors: Lee, C; Liang, L W; Hasegawa, K; Maurer, M S; Tower-Rader, A; Fifer, M A; Reilly, M P; Shimada, Y J Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗